Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Tissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore, Singapore.
Exp Biol Med (Maywood). 2024 Jun 27;249:10142. doi: 10.3389/ebm.2024.10142. eCollection 2024.
The cornea is an avascular tissue in the eye that has multiple functions in the eye to maintain clear vision which can significantly impair one's vision when subjected to damage. Peroxisome proliferator-activated receptors (PPARs), a family of nuclear receptor proteins comprising three different peroxisome proliferator-activated receptor (PPAR) isoforms, namely, PPAR alpha (α), PPAR gamma (γ), and PPAR delta (δ), have emerged as potential therapeutic targets for treating corneal diseases. In this review, we summarised the current literature on the therapeutic effects of PPAR agents on corneal diseases. We discussed the role of PPARs in the modulation of corneal wound healing, suppression of corneal inflammation, neovascularisation, fibrosis, stimulation of corneal nerve regeneration, and amelioration of dry eye by inhibiting oxidative stress within the cornea. We also discussed the underlying mechanisms of these therapeutic effects. Future clinical trials are warranted to further attest to the clinical therapeutic efficacy.
角膜是眼睛中的一种无血管组织,具有维持清晰视力的多种功能,当受到损伤时,会显著损害视力。过氧化物酶体增殖物激活受体 (PPARs) 是一组核受体蛋白,由三种不同的过氧化物酶体增殖物激活受体 (PPAR) 异构体组成,即 PPARα (α)、PPARγ (γ) 和 PPARδ (δ),已成为治疗角膜疾病的潜在治疗靶点。在这篇综述中,我们总结了目前关于 PPAR 药物治疗角膜疾病的文献。我们讨论了 PPAR 在调节角膜伤口愈合、抑制角膜炎症、新生血管形成、纤维化、刺激角膜神经再生以及通过抑制角膜内氧化应激改善干眼症方面的作用。我们还讨论了这些治疗效果的潜在机制。需要进行未来的临床试验来进一步证实其临床治疗效果。